Welcome to an environment of encompassing Alpha-1 support, brought to you by ARALAST NP augmentation therapy. Our purpose? To provide you with continuous support that's easy to access online or over the phone.

Want to talk to an ARALAST NP AATmosphere Representative, Specialized Nurse, Alpha-1 Advocate (person with Alpha-1), or Insurance Specialist?

Just call 1-866-ARALAST toll-free, Monday through Friday, 8:30am to 5:30pm ET.

ARALAST NP [Alpha₁-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A₁-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A₁-PI deficiency has not been established.

Important Safety Information

• ARALAST NP is contraindicated in individuals with selective IgA deficiencies (IgA level less than 15 mg/dL) who have known antibody against IgA, since they may experience severe reactions, including anaphylaxis to IgA, which may be present in small quantities in the final drug product.
• ARALAST NP is derived from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
• The most common adverse events deemed related to ARALAST NP included: headache (4 of 61 [7%] events) and musculoskeletal discomfort (4 of 61 [7%] events).

Please see the ARALAST NP Full Prescribing Information.

Intended for US Audience Only.

Copyright © 2007-2009, Baxter Healthcare Corporation. All rights reserved.